8-K: Integrated BioPharma Q3 Revenue Dips 6.6% to $12.7M

Integrated BioPharma, Inc. reported a 6.6% decrease in revenue to $12.7 million for the quarter ended September 30, 2025, alongside declines in operating and net income.

Summary

• Revenue for the quarter ended September 30, 2025, was $12.7 million, a decrease of $0.9 million or approximately 6.6% compared to $13.6 million for the quarter ended September 30, 2024.
• Operating income for the quarter ended September 30, 2025, was approximately $0.2 million, down from approximately $0.5 million in the prior year's comparable quarter.
• Net income for the quarter ended September 30, 2025, was approximately $0.1 million ($123,000), a decrease from approximately $0.3 million ($259,000) in the prior year's comparable quarter.
• Basic and diluted net income per common share were $0.00 for the quarter ended September 30, 2025, compared to $0.01 for the quarter ended September 30, 2024.
• Revenue from the two largest customers in the Contract Manufacturing Segment represented approximately 87% of total revenue in the quarter ended September 30, 2025, compared to 85% in the prior year's comparable quarter.

Sentiment

Score: 3

Explanation: The company reported significant declines in revenue, operating income, and net income year-over-year. Basic and diluted EPS fell to $0.00. The high customer concentration also presents a notable risk.

Positives

• The company maintained positive operating income of approximately $0.2 million for the quarter.
• The company maintained positive net income of approximately $0.1 million for the quarter.
• The company continues its operations in the manufacturing, distribution, marketing, and sales of vitamins, nutritional supplements, and herbal products.

Negatives

• Total revenue decreased by $0.9 million, or 6.6%, from $13.6 million in Q3 2024 to $12.7 million in Q3 2025.
• Operating income declined significantly from approximately $0.5 million in Q3 2024 to $0.2 million in Q3 2025.
• Net income decreased from approximately $0.3 million in Q3 2024 to $0.1 million in Q3 2025.
• Basic and diluted net income per common share fell from $0.01 in Q3 2024 to $0.00 in Q3 2025.
• High customer concentration, with two largest customers accounting for approximately 87% of total revenue in Q3 2025.

Risks

• Changes in general economic and business conditions.
• Loss of market share through competition.
• Introduction of competing products by other companies.
• The timing of regulatory approval and the introduction of new products by INBP.
• Changes in industry capacity.
• Pressure on prices from competition or from purchasers of INBP's products.
• Regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry.
• Regulatory obstacles to the introduction of new technologies or products that are important to INBP.
• Availability of qualified personnel.
• The loss of any significant customers or suppliers.
• Inflation, including inflationary pressures from any tariffs, and tightened labor markets.
• Ability to expand the customer base.

Future Outlook

The filing contains standard boilerplate forward-looking statements acknowledging risks and uncertainties that could cause actual results to differ materially from expectations. It does not provide specific guidance or projections for future periods.

Management Comments

• "Our revenue decreased by approximately 7% in the quarter ended September 30, 2025 from the quarter ended September 30, 2024 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 87% and 85% of total revenue in the quarters ended September 30, 2025 and 2024, respectively."

Industry Context

Integrated BioPharma operates in the vitamins, nutritional supplements, and herbal products sector, which is part of the broader nutraceutical and pharmaceutical manufacturing industry. The reported decline in revenue and profitability could reflect increased competition, pricing pressures, or shifts in consumer demand within this market, or specific challenges related to their contract manufacturing segment. The high customer concentration (87% from two customers) indicates significant reliance on a limited number of clients, a common characteristic in contract manufacturing but also a notable risk factor.

Stakeholder Impact

• Shareholders: Negative impact due to decreased revenue, operating income, net income, and EPS. The stock price may be negatively affected.
• Employees: Potential impact if financial declines lead to cost-cutting measures, though not explicitly stated.
• Customers: The high concentration of revenue from two customers suggests these relationships are critical. Any changes with these customers could have a significant impact.
• Suppliers: No direct impact mentioned, but overall business health could affect supplier relationships in the long term.
• Creditors: No direct impact mentioned, but declining profitability could affect creditworthiness over time.

Key Dates

Recommendation

The company's financial performance for the quarter ended September 30, 2025, shows a clear negative trend with declines across all key metrics including revenue, operating income, net income, and earnings per share. The significant customer concentration (87% from two customers) adds a substantial risk factor, making the company highly vulnerable to changes in these relationships. Given the deteriorating financial results and inherent business risks, a seasoned investor would likely recommend selling or avoiding the stock until there is evidence of a turnaround or diversification of its customer base.

Keywords

Biopharma, Nutritional Supplements, Vitamins, Herbal Products, Contract Manufacturing, Financial Results, Quarterly Report, INBP, SEC Filing, Earnings